Pharmacy Benefit Managers Are The Wrong Target In Biden’s Quest To Reduce Drug Prices

Prescription drug prices remain high despite the fact that the Biden Administration—and its predecessors—have declared reducing prices as a top priority, and the public has been demanding action on th...

Viatris stock slides 24% as analysts say sale of biosimilars to Indian partner removes key growth driver

Viatris Inc. said Monday it has agreed to combine its biosimilars portfolio with privately held Indian company Biocon Biologics Ltd. for up to $3.335 billion, as part of a broader overhaul of its busi...

Viatris to Sell Biosimilars Business for $3 Billion. Shares Tumble.

Viatris will sell the biosimilars business of the former Mylan to the Indian drugmaker Biocon for as much as $3.3 billion. Dreamstime Text size Viatris , the company formed in 2020 through a merger of...